List View

By /

Clear

Displaying 1,151 - 1,175 of 2,995

Liver and Hepatic Malignancies: Times to Overcome Challenges

Liver and Hepatic Malignancies: Times to Overcome Challenges

Developing Targeted therapy for GU malignancies

Developing Targeted therapy for GU malignancies

Brain Tumors and Sarcomas: New Developments

Brain Tumors and Sarcomas: New Developments

Targeted Therapy for Ovarian and Uterine Tumors

Targeted Therapy for Ovarian and Uterine Tumors

Head and Neck Cancers

Head and Neck Cancers

EGFR and Resistant Mechanisms

EGFR and Resistant Mechanisms

ALK, ROS-1, RET and MET

ALK, ROS-1, RET and MET

NTRK and Antibody Drug Conjugates in NSCLC

NTRK and Antibody Drug Conjugates in NSCLC

Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance

Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance

Update on Novel Therapies for NHL

Update on Novel Therapies for NHL

Role of Immunotherapy in Myeloma

Role of Immunotherapy in Myeloma

AML: Where Are We Now and Where Are We Going?

AML: Where Are We Now and Where Are We Going?

Update on Therapy Options for Untreated and Relapsed CLL

Update on Therapy Options for Untreated and Relapsed CLL

Integrative Oncology: Treatment Approaches for Stress in Cancer Patients and Survivors

Integrative Oncology: Treatment Approaches for Stress in Cancer Patients and Survivors

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains

Current Status of CAR-T Therapy in Hematology

Current Status of CAR-T Therapy in Hematology

Pancreatic Cancer: Are We Finally Making Progress?

Pancreatic Cancer: Are We Finally Making Progress?

Novel Immunotherapy Approaches in Hepatobiliary Malignancies

Novel Immunotherapy Approaches in Hepatobiliary Malignancies

Melanoma as a Paradigm for the Future of Immunotherapy

Melanoma as a Paradigm for the Future of Immunotherapy

Liquid Biopsy: Advances in the Last Decade and Future Directions

Liquid Biopsy: Advances in the Last Decade and Future Directions

Approach to NSCLC Without Targetable Mutations

Approach to NSCLC Without Targetable Mutations

Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1)

Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1)

Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)

Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)

Adjuvant and Neo-adjuvant Therapy for Lung Cancer

Adjuvant and Neo-adjuvant Therapy for Lung Cancer

Renal Cell Carcinoma (RCC): Current Approach to First Line Therapy and Beyond

Renal Cell Carcinoma (RCC): Current Approach to First Line Therapy and Beyond